PDGFRA and neoplasm: Anlotinib is a novel small-molecule tyrosine kinase inhibitor (TKI) that mainly targets vascular endothelial growth factor receptor 1–3 (VEGFR 1–3), fibroblast growth factor receptor 1–4 (FGFR 1–4), platelet-derived growth factor receptor-alpha (PDGFR-α), platelet-derived growth factor receptor-beta (PDGFR-β), and the stem cell factor receptor c-KIT to inhibit tumor angiogenesis and growth.21